Novel Therapeutics

//Novel Therapeutics
Novel Therapeutics 2018-06-01T12:44:00+00:00
Novel mab therapeutics

Expanding Our Pipeline to Include Innovative
mAb Therapeutics

Oncobiologics is expanding our pipeline to include innovative mAb candidates. We have begun work on ONS-5010, a proprietary innovative drug product candidate that will not use the biosimilar regulatory pathway. We are planning to initiate clinical trials in 2018 for ONS-5010.